Benitec Biopharma Limited
(ASX:BLT)Chief Business Officer Carl Stubbingspresents at the ASX Investor Series in Sydney.
The biotechnology company working on gene silencing therapies for a range of debilitating illnesses and its treatments for HIV has been approved for stage 2 trials in the US.
Mr Stubbings’ presentation is titled, “Gene Silencing: A quiet revolution in healthcare” and covers the company’s investment case, value proposition and recent highlights.
